Abstract
* The antiarrythmic drug dronedarone (Multaq) shouldn't be used to treat permanent atrial fibrillation. A large clinical trial found that dronedarone increased the rates of death, stroke, and hospitalization for heart failure in this population.
* Dronedarone is approved to treat nonpermanent atrial fibrillation; at this time it may still be used for this indication.